Promega Assay Reagents to Support Complement-ARIE Mechanistic Toxicology Research
Archived on October 6, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 12:00 PM EDT
- Posted
- September 16, 2026
- Notice type
- Combined Synopsis/Solicitation
- Set-aside
- No Set aside used
- NAICS
- 325413: In-Vitro Diagnostic Substance Manufacturing
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH OLAO
- Place of performance
- Durham, North Carolina, 27709
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- 75N98026Q01226
- Notice ID
- cf8a09ad952f47aa87c30c2c9f377554
Description
1.0 DESCRIPTION
This is a combined synopsis/solicitation for commercial products prepared in accordance with RFO FAR Part 12. This announcement constitutes the only solicitation. Offers are being requested, and a separate written solicitation will not be issued.
Solicitation No. 75N98026Q01226 is issued as a Request for Quotation (RFQ) for Promega assay reagents to support Complement-ARIE mechanistic toxicology research.
The Government intends to award a purchase order on a sole-source basis to Promega Corporation based on the Government's determination that Promega Corporation is the only source identified as capable of satisfying the Government's requirements. However, all responsible sources may submit a quotation that demonstrates their ability to satisfy the complete requirements identified in this RFQ and the attached requirements document. All timely quotations will be considered by the Government.
This RFQ is being posted to the Governmentwide Point of Entry (GPE) in accordance with RFO FAR 5.201. This acquisition will be conducted in accordance with RFO FAR Part 12 – Acquisition of Commercial Products and Commercial Services, using the simplified procedures at RFO FAR 12.201-1.
The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), intends to procure, on a sole source basis, Promega assay reagents from the manufacturer, Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin 53711.
The Promega assay reagents are required to support Complement-ARIE research conducted by the National Center for Advancing Translational Sciences (NCATS) and NIEHS through the Mechanistic Toxicology Branch (MTB) within the Division of Translational Toxicology (DTT). The reagents will be used to assess cell viability, liver injury, liver function, oxidative stress, antioxidant responses, and cellular bioenergetics in human three-dimensional microphysiological systems and will complement cell painting and omics endpoints. Continued use of the specified assay reagents is necessary to support the established experimental approach, maintain consistency and comparability of research results, and provide the required sensitivity for evaluating toxicity responses in small three-dimensional microtissue models.
Due to the specialized nature of the Complement-ARIE research and the Government’s requirement for the specific combination of assay reagents, luminescence/chemiluminescence-based detection, toxicological endpoints, and compatibility with the established experimental approach, the Government intends to procure these supplies on a sole-source basis from Promega Corporation. Promega Corporation manufactures the assay reagents identified in the Government’s requirement and, based on the market research conducted, is the only source identified that can satisfy the Government’s requirements. The Government has determined that these requirements are necessary to support the established research methodology, maintain comparability and reproducibility of results, and enable integration of the assay results with existing cell painting and omics-based analyses.
The contractor shall provide the Promega assay reagents identified in the Government’s requirement and associated quotation. The reagents shall support measurement of cell viability, liver injury, liver function, oxidative stress, antioxidant responses, and cellular bioenergetics in human three-dimensional microphysiological systems. The contractor shall deliver the required supplies to NIEHS in Rall Building 101, laboratories E144-146, located at 111 T.W. Alexander Drive, Research Triangle Park, North Carolina 27709. Acceptance will be demonstrated by successful delivery and the successful performance of the specified assays within the NIEHS laboratory. There is no travel for this purchase.
Required delivery date: September 25, 2026
Delivery Location: NIEHS, Rall Building 101, Laboratories E144-146, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709
The applicable NAICS code is 325413 – In-Vitro Diagnostic Substance Manufacturing. The applicable PSC is 6550 – In Vitro Diagnostic Substances, Reagents, Test Kits and Sets.
Please see the attached requirements document titled “75N98026Q01226 – Requirements Document” for additional information.
2.0 UNIQUE QUALIFICATIONS OF THE CONTRACTOR
The proposed contractor, Promega Corporation, is the manufacturer of the required assay reagents for the Complement-ARIE research conducted by NCATS and NIEHS. The required supplies involve specialized assay reagents designed to measure cell viability, liver injury, liver function, oxidative stress, antioxidant responses, and cellular bioenergetics in human three-dimensional microphysiological systems. The requested reagents also provide luminescence/chemiluminescence-based detection and are intended to complement established cell-painting and omics-based endpoints.
The Promega assay reagents are specialized research products that are required to support the Government’s established experimental approach for evaluating toxicity-induced liver injury and associated cellular responses in human three-dimensional microphysiological systems. Due to the specific combination of required toxicological endpoints, detection technology, and compatibility with the established Complement-ARIE research methodology, use of an alternate source could require modifications to the experimental design and methodologies, affect assay sensitivity, and reduce the comparability and reproducibility of results across the research program. Accordingly, Promega Corporation is the only identified responsible source capable of providing the complete combination of assay reagents required to meet the Government’s scientific and technical requirements while maintaining the established experimental approach.
BASIS FOR AWARD
The Government intends to issue a firm-fixed-price purchase order to Promega Corporation. However, all timely quotations received will be considered. To be considered for award, a quotation must demonstrate that the products offered satisfy all the Government's scientific and technical requirements identified in this RFQ and the attached requirements document. Award will be made to the responsible quoter whose quotation satisfies the Government's requirements and whose price is determined fair and reasonable.
RESPONSE INSTRUCTIONS
The response and any other information furnished must be in writing and must contain material in sufficient detail to allow the Office of Acquisition and Logistics Management (OALM) to determine whether the respondent can fulfill the requirement. Quotations shall identify the products being offered, manufacturer and part numbers, quantities, unit and total prices, delivery schedule, and sufficient technical information to demonstrate that the products offered satisfy all of the Government's scientific and technical requirements identified in the attached requirements document.
All responses must be sent via email to Contract Specialist, Jordan Neal, at Jordan.Neal@nih.gov, copying Contracting Officer, Alice Pagán Pereira, at Alice.Pagan@nih.gov by no later than 12:00 pm Eastern Time on Monday, September 21, 2026.
To be eligible for award, the contractor must be registered in System for Award Management (SAM.gov) in accordance with applicable requirements. Reference: 75N98026Q01226 on all correspondence.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Files (1)
- Download
75N98026Q01226 - Requirements Document.pdf
165 KBAdded in Combined Synopsis/Solicitation version 3Posted
Lifecycle
- 3Version 3Combined Synopsis/SolicitationArchivedCurrent
Promega Assay Reagents to Support Complement-ARIE Mechanistic Toxicology Research
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing) and the small business size standard is 1,250 employees. This requirement is not set aside for small business. | - | Combined Synopsis | 11/05/2026 |
Requesting procurement of a high-throughput FDA approved molecular diagnostic testing system and reagents through a rental purchase agreement. Purchase order is requested to order additional specific products throughout the year necessary to perform rapid syndromic infectious disease diagnostic panels. | - | Market Research | 11/27/2026 |
BD Micro Reagents and Service | - | Awarded | Open |
CTX BD Micro Reagents and Service Contract | - | Awarded | Open |
NTX blood bank cost per test | - | Awarded | Open |
Additional Details
Solicitation Number
75N98026Q01226
Archive Date
Oct 6, 2026
Office Address
BETHESDA, MD, 20892